ANVISA Regulatory Changes: Impact on Foreign Pharma Expedited Approvals

Key Takeaways

• Regulatory reliance formalized: ANVISA recognizes eight Equivalent Foreign Regulatory Authorities (AREEs) including FDA, EMA and Health Canada for optimized review pathways under IN 289/2024.
• Priority timelines defined: Marketing authorization reviews complete in 120 days; post-registration changes in 60 days; clinical trial approvals in 45 days per RDC 204/2017.
• Digital submission mandatory: ANVISA's Solicita system and Electronic System of Information (SEI) enable fully electronic petitioning with real-time status tracking.
• Data exclusivity unchanged: Brazil maintains five-year data exclusivity for new chemical entities under Law 9,787/1999 regardless of reliance pathway used.

What Changed in ANVISA's Regulatory Framework?

ANVISA (Agência Nacional de Vigilância Sanitária) has transformed its approach to foreign pharmaceutical approvals. The agency now actively participates in international harmonization initiatives including ICH (International Council for Harmonisation), PIC/S (Pharmaceutical Inspection Cooperation Scheme) and IMDRF (International Medical Device Regulators Forum).

The 2024 regulatory updates mark a decisive shift. Normative Instruction 289/2024 established the complete list of Equivalent Foreign Regulatory Authorities (AREEs) and detailed criteria for optimized analysis through reliance. This built upon RDC 204/2017, which created priority review categories for medicines addressing unmet medical needs, rare diseases, and public health priorities.

Why it matters: Brazil represents Latin America's largest pharmaceutical market with over 215 million people. Previous independent review processes required 12–24 months or longer. The reliance pathways allow foreign companies with FDA, EMA or Health Canada approvals to achieve faster Brazilian market access without duplicate clinical trials or redundant manufacturing assessments. Companies should also review ANVISA's serialization requirements for supply chain compliance.

How Does ANVISA's Reliance Mechanism Work?

ANVISA defines reliance as "the act whereby a regulatory authority in one jurisdiction takes into account and gives significant weight to assessments performed by another regulatory authority." This WHO definition underpins ANVISA's approach: the agency uses foreign authority work as part of its decision-making while retaining full sovereignty over final approvals. Foreign sponsors should understand how ANVISA's clinical trial regulations interact with reliance pathways.

The mechanism operates through three distinct approaches:

• Reliance: ANVISA uses foreign authority assessments partially or fully within its own review process. The final decision remains with ANVISA.
• Recognition: ANVISA officially recognizes another authority's decision without reevaluating underlying data.
• Work-sharing: Multiple authorities collaborate simultaneously on assessments, dividing tasks for efficiency.

For medicines, vaccines and biological products, ANVISA accepts approvals from FDA (USA), EMA (EU), Health Canada, MHRA (UK), Swissmedic (Switzerland), TGA (Australia), PMDA (Japan) and WHO Prequalification. Active pharmaceutical ingredients have additional recognition through EDQM (European Directorate for the Quality of Medicines).

Which Products Qualify for Priority Review?

RDC 204/2017 establishes specific criteria for priority classification. Marketing authorization requests qualify when meeting one or more conditions:

• Treatment, diagnosis or prevention of rare diseases (orphan drugs)
• Products addressing unmet medical needs with no therapeutic alternatives in Brazil
• Medicines for neglected diseases affecting vulnerable populations
• Treatments targeting epidemics or pandemics
• Products with risk of market shortage impacting public health

Clinical trial prior approvals (DDCM and DEEC processes) receive priority for products treating serious or life-threatening conditions, pediatric indications, and studies conducted primarily in Brazil.

The timelines are strict. Marketing authorization decisions must occur within 120 days from protocol. Post-registration changes take 60 days. Clinical trial prior approvals receive first manifestation within 45 days. RDC 811/2023 amended procedures so requests not meeting priority criteria transfer to ordinary analysis queue after 45 days rather than facing outright rejection.

What Are the Digital Submission Requirements?

ANVISA mandates electronic petitioning through its Solicita system (Sistema de Peticionamento). Companies must obtain Brazilian CNPJ registration and configure appropriate user profiles before submitting. The system supports modern browsers including Chrome, Firefox and Edge through Gov.br authentication.

The petitioning workflow includes:

1. Primary petition creation with electronic forms FP1 and FP2
2. Document upload through secure portal
3. Tax payment via Guia de Recolhimento da União (GRU) or PagTesouro
4. Real-time status tracking through process monitoring dashboards
5. Electronic deficiency responses within the same system

SEI (Sistema Eletrônico de Informações) provides additional electronic process management. Users can petition documents in existing processes, sign contracts and verify document authenticity. The SEI petitioning system does not handle information requests or process copies—those require separate channels through ANVISA's Citizen Service Center.

How Does Data Exclusivity Work in Brazil?

Brazil protects undisclosed test data submitted for marketing approval. Law 9,787/1999, which amended the original health surveillance law, established the framework for data exclusivity protection.

New chemical entities receive five years of exclusivity. During this period, generic manufacturers cannot reference the innovator's clinical data in their ANVISA submissions. The protection applies to undisclosed test data concerning safety and efficacy.

The reliance pathways do not alter data exclusivity duration or scope. However, faster innovator approvals through reliance may accelerate when exclusivity periods begin. For generic and biosimilar manufacturers, reliance pathways enable faster entry once exclusivity expires since these competitors can reference foreign regulatory decisions more readily.

What Are the Mandatory Requirements for Foreign Companies?

Three requirements apply regardless of reliance pathway eligibility:

• Portuguese labeling: All pharmaceutical products require Portuguese-language package inserts, patient information leaflets and promotional materials. Translation and regulatory writing typically require 3–6 months.
• Local representation: Foreign companies must designate a Brazilian partner or establish a local entity responsible for regulatory compliance, adverse event reporting and post-market surveillance.
• Electronic system registration: Companies need active CNPJ registration with ANVISA and appropriate user profiles in the Solicita or legacy petitioning systems.

Good Manufacturing Practice (GMP) certification remains mandatory. Manufacturing facilities must hold valid GMP certificates from ANVISA or recognized PIC/S member authorities. Products submitted through reliance must have identical characteristics to those approved by the reference authority.

What Should Companies Monitor Going Forward?

ANVISA continues expanding its reliance program. Future developments may include additional AREEs, broader product category coverage and deeper harmonization with Latin American counterparts like COFEPRIS (Mexico) and ANMAT (Argentina). Companies should monitor ANVISA's oncology fast-track programs for additional expedited pathways.

Compared with the previous framework requiring independent Brazilian review for all products, the current system offers substantial time and cost savings. Companies with existing FDA or EMA approvals gain clear competitive advantages over those pursuing traditional pathways.

What to watch next: Monitor ANVISA's guidance on reliance implementation, potential updates to data exclusivity regulations and further digitization of submission processes. Companies should conduct early regulatory assessments to determine eligibility, establish local partnerships and invest in Portuguese labeling early in market entry planning.

Frequently Asked Questions

Primary Sources

1. ANVISA RDC 204/2017 — Establishes priority review criteria and timelines for drug registration, post-registration and clinical research approvals.
2. ANVISA Regulatory Reliance Program — Official documentation of reliance mechanisms, AREE list and applicability by product type.
3. Brazil Law 9,787/1999 — Establishes generic medicines framework and data exclusivity protections for new chemical entities.
4. ANVISA Solicita System — Official electronic petitioning platform for drug registration submissions.
5. WHO Good Regulatory Practices (2021) — Defines reliance, recognition and work-sharing concepts adopted by ANVISA.
6. ANVISA RDC 954/2024 — Establishes simplified procedures for registration, post-registration and renewal of medicines.